

## **Inserm Transfert has obtained ISO 9001 v2015 certification for the quality management of all its activities.**

**This certification, which concerns all the company's activities, reflects the Inserm Transfert approach to quality, which it launched in 2010.**

Paris, 6 November 2018 – Inserm Transfert, the private subsidiary of Inserm responsible for value creation of Inserm innovations, today announced that it has been ISO 9001 v2015 certified for all its activities.

Since 2010, Inserm Transfert has been ISO 9001 v2008 certified for several of its activities. However, this new global certification relates to all the company's business.

This comprehensive quality approach has been an internal call to action for all the teams who adhered to the project. This success validates the quality of the services and expertise provided by Inserm Transfert.

This approach to quality management reflects the company's desire to continuously strengthen and adapt its standards to ensure it responds to the needs and expectations of clients and partners (researchers, industrial partners, etc.) in the context of technology transfer.

The certification was obtained by demonstrating that four major quality objectives had been achieved:

- Improvement of operational performance
- Strengthening of internal expertise
- Value creation of partners' assets (scouting, evaluating, protecting intellectual property, maturing, guiding, funding, establishing partnerships)
- Guarantee compliance of staff to continual improvement objectives.



*“Our business is to support innovation that comes from the results of research, to protect this innovation and to facilitate the technology transfer, with the ultimate aim of creating medicines which can be developed by start-ups or industrial partners, with high quality follow-up”, explains Pascale Augé, President of the Inserm Transfert Board of Directors. “We wanted to improve the quality approach which already existed at the operational level. Certification of our practices facilitates exchanges and cross-sectoral approaches within the company, it consolidates our operational tools and enables us to better anticipate in order to improve our responses in the service of innovation and the satisfaction of researchers.”*

*“In 2017, we began to rethink the cartography of our quality management system, describing the processes and working on a normative approach which positions the company within its ecosystem, taking into account the issues, risks and opportunities and the needs and expectations of our stakeholders, setting out our quality policy and ensuring client satisfaction in line with the services we offer”, says Patricia Joseph-Mathieu, Quality Manager of Inserm Transfert. She continues: “Launching a quality approach involves formalising day-to-day actions, thinking on the processes which will guarantee and improve the quality of our activities and create a shared vision of what quality is and what it should be.”*

The approach to quality management has enabled us to improve efficiency and effectiveness when responding to our partners and clients. It has consolidated our business interfaces, improved communication between the various departments, and made it easier for information to circulate, ensuring everyone has the right information at the right time, from the right person, with the constant objective of satisfying our clients and partners. The certification will enable Inserm Transfert to respond even more effectively to international operating standards and to highlight the quality of its services.

#### **About Inserm Transfert**

Inserm Transfert, the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), is responsible for value creation of Inserm innovations in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000, and manages, under a Public Service Management Contract (*Délégation de Service Public*), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and start-ups incorporation.

Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research.

In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, the Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created.

[www.inserm-transfert.com](http://www.inserm-transfert.com)

#### Contacts:

**Agence Acorelis** - Gilles Petitot – +33 (0)6 20 27 65 94 – [gilles.petitot@acorelis.com](mailto:gilles.petitot@acorelis.com)

**Inserm Transfert** - Ingrid Hargot – +33 (0)1 55 03 01 44 - [communication@inserm-transfert.fr](mailto:communication@inserm-transfert.fr)